AIDX

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

424B3 - 20/20 Biolabs, Inc. (0001139685) (Filer)

EFFECT - 20/20 Biolabs, Inc. (0001139685) (Filer)

EFFECT - 20/20 Biolabs, Inc. (0001139685) (Filer)

Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's National Practitioner Network WASHINGTON, Conn. and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases today announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, a leading marketplace that enables functional and integrative medicine practitioners to easily d

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

S-1 - 20/20 Biolabs, Inc. (0001139685) (Filer)

POS AM - 20/20 Biolabs, Inc. (0001139685) (Filer)

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

10-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026 Recent Nasdaq Listing Under Ticker Symbol "AIDX" and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion GAITHERSBURG, Md., March 31, 2026 (GLOBE NEWSWIRE) --  20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the full year

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools  GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company's patented OneTest™ multi-cancer early detection (MCED) blood test. The funding is from the state's Professional and Volunteer Firefighter

Inflammatory Biomarker Tracking Predicted to Enhance  Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20"), 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. ("ROKIT"), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integ

GAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an update on its patented protein tumor marker (PTM) based, machine learning (ML) derived multi-cancer early detection (MCED) methodology in the wake of several recent studies suggesting the expected value of this approach for earlier stage detection compared to stand-alone circulating tumor DNA (ctDNA) based MCEDs. As population-scale cancer screening studies continue to generate trial data and real-world evidence, the medical community, co

4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market leader in cutting-edge, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announces the launch and commercial availability of its OneTest for Longevity solution. The solution uses IBM watsonx.ai – an integrated AI application development studio – to analyze data, to help individuals track chronic inflammation associated with several major chronic diseases. T

GAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced today that it will hold a virtual investor webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time. 20/20 BioLabs President and CEO Jonathan Cohen will host the webinar to discuss the company's recent Nasdaq listing, OneTest™ for Cancer™ AI powered multi-cancer early detection ("MCED") blood test, One Test for Longevity™ expected to be launched before the end February, ongoing initiatives, and upcoming milestones. A question-and